The iShares Nasdaq Biotechnology ETF (IBB) briefly fell more than 2.5 percent, tracking for its first negative day of 2017.
Celgene CEO Mark Alles speaks to CNBC's Meg Tirrell about his drug industry outlook under the Trump administration.
Jim Cramer expects bank and drug stocks to be on the red-hot griddle.
Will the biotech breakout continue? With CNBC's Melissa Lee and the Options Action traders.
Ronny Gal, Sanford C. Bernstein senior analyst, discusses his outlook for the biotech sector.
Buying the biotech ETF during JPMorgan's annual health-care conference has proven to be a profitable trade, research shows.
The "Fast Money" traders weigh in on the health care sector, as the Trump administration attempts to repeal Obamacare.
Jim Cramer outlines why investors need to watch Washington to determine if the Trump rally can continue.
Investors seeking to outperform the market in 2017 should buy the extremes of a so-called barbell strategy, a new study shows.
Is now the time to buy laggards? And is health care ready to break out? With CNBC's Melissa Lee and the Options Action traders.
Michael Yee, RBC Capital Markets, and Michael King, JMP Securities, look back at a very rough year for biotech stocks and discuss whether the sector is primed to take off.
While the markets are mostly lower following the Fed's rate hike decision, the Nasdaq biotech ETF IBB holds gains. CNBC's Jackie DeAngelis reports.
Jim Cramer explains the relationship between Apple and the Federal Reserve, and why it could benefit from a rate hike.
Beaten-up biotech stocks could fall further, according to one technical analyst who sees trouble in the charts.
Health-care stocks haven't gotten the green light many expected from Hillary Clinton's election loss.
CNBC's Meg Tirrell speaks with Celgene CEO Mark Alles at the American Society of Hematology about the company's immunotherapy partnerships and the upcoming Trump administration.
Ana Gupte, Leerink Partners, and Leonard Yaffe, StocDoc Partners, discuss stocks poised to win amid Trump's healthcare reform.
In the likely repeal of the Affordable Care Act, these health-care stocks should perform well, according to some analysts.
If they're right, the average lifespan of 79 years will be a thing of the past, and humans could live for decades longer.
Jim Cramer reflects on the stunning victory of Donald Trump, and how it will impact the stocks that lead the charge in the market.